11548 RESULTS
COMMENT This is an exciting study—it provides the first view into tracer movement through the human subarachnoid space over just a few hours. They find that tracers move in a specific pathway along the arteries before entering brain tissue. This information is im
COMMENT This may have been the fourth randomized Phase 3 trial of a form of methylene blue in various doses by this company. None was statistically significant compared to their contemporaneous controls. The trials used a small dose of HMTM or similar as the cont
COMMENT The saga of “methylene blue,” or derivatives of this dye with various names, including LMT-X/LMTM and HMTM, continues with a presentation of TauRx-sponsored work at ADPD 2024. The history of this drug, which putatively targets tau aggregation at low doses
COMMENT Firstly, I think these results are fantastic and show the possibilities of BBB-crossing immunotherapy. The big question I would have thought is, have the patients been cured? Moreover, or alternatively, if the patients had been treated in their 20s, 30s,
COMMENT The paper by Wilson et al. is extremely timely and important. It attributes a key role to myeloid cells in coping with aging in general, and age-related neurodegenerative diseases in particular, with an emphasis on Alzheimer’s disease, focusing on trigger
COMMENT This paper highlights, and raises questions about, potential crosstalk between the peripheral immune system and central nervous system microglia and how this communication could be a powerful modulator of neurodegeneration. While the authors found very sm
COMMENT Fantastic work by both groups. The work by Jonathan Kipnis and colleagues could provide an additional explanation for why we saw plaque clearance in APP/PS1 mice after optogenetic rescue of slow waves during sleep. kkastanenka_305846 0 Sleep restoration b
COMMENT This is an interesting paper, even though it is not directed toward Alzheimer’s disease. It does make some fundamental observations that are worth noting, and which are pertinent to Alzheimer’s. One is that mitochondrial function influences the activity a
COMMENT We have read the study from Milioto et al. with much interest, because last year we published a clinical study in which we made a similar observation (Gogishvili et al., 2023), namely that while TGF-β1 was increased in dementia compared to controls, it wa
COMMENT This is a huge story. There are many lessons to be learned here. lansburyp_333756 0
COMMENT We are grateful for the comments that Alzforum readers made to our bioRxiv preprint. Brain
COMMENT This represents another advance in C9ORF72 modeling, by placing expression of one of two different artificially engineered DPR proteins (GR or PR) under the control of the endogenous C9ORF72 promoter. Interestingly, the authors found that lower motor neur
COMMENT Norambuena and colleagues used an APP SAA / App NL-G-I knock-in mouse model of AD to demonstrate mitochondrial dysfunction in the very early stage of AD development. It is hard to understand why the authors used a copy model of our App NL-G-F and other kn
COMMENT I’d like to commend the authors on the technical sophistication of the work, for considering the possibility that mitochondria and energy-related metabolism are relevant to AD, and for offering a generally unique and innovative hypothesis. The authors rep
COMMENT Defects in proteostasis and the accumulation of toxic misfolded proteins, as well as mitochondrial dysfunction and a neuroenergetic crisis are intimately linked to each other in the pathogenesis of neurodegenerative diseases. This preprint tries to shed l
